Baird Financial Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Baird Financial Group’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-333	Closed	-$28K	–	1372
2018 Q2	$28K	Hold	333	–	–	﹤0.01%	1274
2018 Q1	$35K	Hold	333	–	–	﹤0.01%	1243
2017 Q4	$43K	Hold	333	–	–	﹤0.01%	1255
2017 Q3	$39K	Sell	333 -62	-16%	-$7.45K	﹤0.01%	1226
2017 Q2	$52K	Buy	395 +62	+19%	+$8.37K	﹤0.01%	1216
2017 Q1	$55K	Buy	+333	New	+$45.1K	﹤0.01%	1207

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

Baird Financial Group's VBIV Position: Q3 2018 in Review

Baird Financial Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2018, closing a stake of 333 shares — an estimated $28K sold.

Baird Financial Group first reported a position in VBIV in Q1 2017 and held it in 6 quarters. The position peaked at $55K in Q1 2017. 40 funds tracked by Wall St. Rank hold VBIV as of Q3 2018.

Baird Financial Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2018 after selling out during the quarter.
Baird Financial Group sold 333 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2018, an estimated $28K.
Baird Financial Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2017 and held it in 6 quarters.
Baird Financial Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $55K in Q1 2017.
40 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2018.

Based on Baird Financial Group's 13F filing for Q3 2018, filed 13 Nov 2018.